Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population
- PMID: 33426547
- PMCID: PMC8323818
- DOI: 10.1039/d0an01769h
Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population
Abstract
Adaptive resistance is a major limitation in the use of targeted therapies for cancer. Using real time biomass tracking, we demonstrate the isolation and identification of rare (1% fraction) diffuse large B cell lymphoma cells resistant to the PI3K inhibitor idelalisib, from an otherwise sensitive population. This technique allows direct study of these rare, drug tolerant cells.
Conflict of interest statement
There are no conflicts of interest to declare.
Figures
References
-
- Hata A. N. Niederst M. J. Archibald H. L. Gomez-Caraballo M. Siddiqui F. M. Mulvey H. E. Maruvka Y. E. Ji F. Bhang H.-E. C. Krishnamurthy Radhakrishna V. Siravegna G. Hu H. Raoof S. Lockerman E. Kalsy A. Lee D. Keating C. L. Ruddy D. A. Damon L. J. Crystal A. S. Costa C. Piotrowska Z. Bardelli A. Iafrate A. J. Sadreyev R. I. Stegmeier F. Getz G. Sequist L. V. Faber A. C. Engelman J. A. Nat. Med. 2016;22:262–269. doi: 10.1038/nm.4040. - DOI - PMC - PubMed
-
- Song K.-A. Hosono Y. Turner C. Jacob S. Lochmann T. L. Murakami Y. Patel N. U. Ham J. Hu B. Powell K. M. Coon C. M. Windle B. E. Oya Y. Koblinski J. E. Harada H. Leverson J. D. Souers A. J. Hata A. N. Boikos S. Yatabe Y. Ebi H. Faber A. C. Clin. Cancer Res. 2018;24:5658. doi: 10.1158/1078-0432.CCR-18-0304. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
